Grp94 Allosteric Inhibitors for Selective Hsp90 Paralogue Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacologic Hsp90 inhibitors are non-selective, making it difficult to differentiate the role of individual paralogs in cancer cells, as they bind equally well to multiple Hsp90 proteins, hindering the understanding of their specific biological effects.
Innovation Solution
Development of Grp94-specific inhibitors that target the allosteric binding site of Grp94, utilizing structural differences to achieve high specificity and inhibit Grp94 without affecting other Hsp90 paralogs like Hsp90α, Hsp90β, and Trap-1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-Hsp90 inhibitors are used, then Hsp90 chaperone function is inactivated, but selectivity among Hsp90 paralogs is lost
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that interact with unique structural characteristics of Grp94's ATP-binding pocket. The inhibitors contain substituents at positions 2 and 6 of the purine ring that specifically fit Grp94's binding cavity, while pan-Hsp90 inhibitors lack these differentiating features. This allows the inhibitor to selectively bind Grp94 without affecting other Hsp90 paralogs, resolving the contradiction between therapeutic activity and selectivity.
2Reliability
If Grp94 inhibitors are used, then Grp94 chaperone function is inhibited, but feedback up-regulation of heat shock proteins occurs with pan-Hsp90 inhibitors
Solution Approach 1:
The patent extracts the Grp94-specific binding interaction from the general Hsp90 inhibitor class by incorporating specific substituents (e.g., 2-chlorophenyl at position 2 and isoxazole at position 6 of the purine ring) that are uniquely accommodated by Grp94's ATP-binding pocket. This extraction of Grp94-specificity allows the inhibitor to selectively target Grp94 without affecting other Hsp90 paralogs, thereby preventing the feedback up-regulation of heat shock proteins that occurs with pan-Hsp90 inhibition.
3Productivity
If non-selective Hsp90 inhibitors are used, then cancer cells are treated, but differentiation of individual paralog roles is prevented
Solution Approach 1:
The patent applies parameter changes by systematically varying the substituent parameters at positions 2 and 6 of the purine ring to optimize Grp94 selectivity. The specific combination of substituents (2-chlorophenyl at position 2, isoxazole at position 6) creates a molecular parameter profile that matches Grp94's binding pocket characteristics. This parameter optimization enables selective Grp94 inhibition while preserving the ability to study individual paralog roles in cancer biology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Grp94 inhibitors provide therapeutic benefits in treating various cancers by selectively targeting Grp94, avoiding feedback up-regulation of heat shock proteins like Hsp70, and inducing apoptosis in cancer cells overexpressing tyrosine kinase receptors.
Implementation Method 1
Grp94-specific inhibitors that target the allosteric binding site of Grp94, utilizing structural differences to achieve high specificity and inhibit Grp94 without affecting other Hsp90 paralogs like Hsp90α, Hsp90β, and Trap-1
Data Source
AI summary
The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.